Kornimate/medical-research-clean huggingface dataset:
effects of oxytocin dose frequency on behavioral and neural responses

Conditions: Healthy

Summary: the main aim of the study is to examine effects of different dose frequencies of repeated oxytocin administration on neural and behavioral markers of oxytocin in healthy male subjects. in addition modulatory effects of autism traits and oxytocin receptor genotype (oxtr) will be explored.

in the present study, healthy male subjects will be screened according to the study inclusion criteria. after enrollment buccal swaps will be collected for genotyping and subjects will be randomly assigned to three experimental groups that will receive treatment for 5 subsequent days: (1) placebo for five days, (2) oxytocin on days 1, 3 and 5, or (3) oxytocin for five days. behavioral measures, task-based and resting fmri will be assessed after the first treatment (acute effects) and the last treatment (chronic effects). the task-based fmri will employ an implicit emotional face processing paradigm and ratings of the facial emotions will be collected after the fmri. moreover, to control for potential confounding effects of relevant traits all participants will complete the following questionnaires: interpersonal reactivity index (iri),beck depression inventory (bdi), state-trait anxiety inventory (stai). to explore potential modulatory effects of trait autism, all subjects will be administered the autism spectrum quotient (asq) scale to assess pre-treatment autism traits.

Eligibility criteria:
inclusion criteria: * healthy adult males exclusion criteria: * past or current psychiatric or neurological disorder head trauma substance abuse medication fmri contraindications (e.g. metal implants)

Keywords: multiple doses oxytocin genotype autism trait
coronary microcirculatory disease and inflammation in patients with chronic coronary syndrome and no significant coronary artery stenosis

Conditions: Coronary Artery Disease; Ischemia and No Obstructive Coronary Arteries; Ischemic Heart Disease; Microvascular Angina; Vasospastic Angina

Summary: patients with chronic coronary syndromes (ccs) diagnosed without significant lesions in invasive coronary angiography (ischemia non-obstructive coronary artery disease - inoca) represent approximately 50% of all patients with ccs. results of fame study clearly showed that evaluation of coronary circulation should not be accomplished only with visual assessment in resting conditions. current european society of cardiology guidelines of diagnosis and treatment of ccs published in 2019 emphasize the necessity of performing complex coronary physiology assessment. invasive physiological measurements and vasoreactivity provocative tests emerged as key tools to differentiate between vasospastic angina, microcirculatory angina, overlap of both conditions or non-cardiac disease. according to contemporary literature, identification of heterogeneity of patients with inoca is crucial for determination of adequate treatment. an appropriate pharmacotherapy has a potential to improve outcomes including grade of angina, quality of life, exertional tolerance and most important - macce (major adverse cardiac and cardiovascular events) free survival. however, there is a lack of evidence on each of the subtypes of inoca especially in those with signs and symptoms of vasospasm in provocative test but without visual spasm in epicardial vessels.


Eligibility criteria:
inclusion criteria: 1. diagnosed chronic coronary syndrome ccs ≥ 2. 2. evidence of myocardial ischemia (positive result of non-invasive stress test). 3. informed consent. 4. age at least 18 years. exclusion criteria:

Keywords: coronary artery disease ischemia and no obstructive coronary arteries ischemic heart disease microvascular angina vasospastic angina coronary microvascular dysfunction coronary microcirculation endothelial dysfunction
uremic pruritus, cytokines and polymethylmethacrylate artificial kidney

Conditions: Uremia; Pruritus

Summary: background: uremic pruritus is one of the common complications in long-term dialysis patients. in general, many factors including xerosis, elevated serum calcium, phosphate, calcium-phosphate product, hyperparathyroidism and inadequate dialysis may contribute to it. recently, researchers reported that immuno-hypothesis with high serum level of cytokines could be the cause of uremic pruritus. polymethylmethacrylate (pmma) artificial kidney (ak) has been reported to adsorb more serum cytokines than other high flux artificial kidneys. methods: in july 2006, 30 patients with severe uremic pruritus from 300 chronic hemodialysis patients in a single center entered this prospective study. their dialyzers were changed to pmma ak for 4 weeks. the severity of pruritus was evaluated every week using the results of a questionnaire (pruritus score). laboratory assays including pre-dialysis serum blood urea nitrogen, creatinine, β2-microgblubulin (β2m), calcium, phosphate, intact parathyroid hormone (ipth), total co2, ferritin, hematocrit, high sensitivity c-reactive protein (hscrp), il-1, il-2, il-6, il-18, tnf-α, kt/v and β2m clearance were measured before and at the end of 4 weeks of pmma ak use. expected results:to prove the pmma membrane could improve the uremic pruritus and to reveal the effect of pmma membrane on serum level of possible factors contributing to uremic pruritus.


Eligibility criteria:
inclusion criteria: * patients with chronic pruritus (\>3 months) were screened using traditional visual analogue scale (vas) and then scored using a pruritus questionnaire (pruritus scoring system). * other inclusion criteria were that patients enrolled should be dialysed for 4 hours, three times a week, with kt/v \>1.2, serum albumin\> 3.0 mg/dl, hematocrit \> 24%, ferritin \< 900 ng/ml, phosphate \<7 mg/dl, corrected calcium \<11 mg/dl, calcium-phosphate product \< 70, intact parathyroid hormone (ipth) \<600 pg/ml, and normal serum level of alanine aminotransferase and bilirubin in past 3 months. exclusion criteria: * pruritus unrelated to renal failure * evidence of malignancy * liver cirrhosis diagnosed by echogram or admission within 3 months of the start of the study.

Keywords: uremic pruritus cytokines polymethylmethacrylate artificial kidney hemodialysis
comparison between free thyroxine and thyroid stimulating hormone levels on melasma severity

Conditions: Melasma

Summary: the objective of the study was to compare the level of serum ft4 and tsh in patients with mild melasma and moderate-severe melasma. the determination of melasma lesion could also be known by using janus ii facial analysis uv light and polarization light to analyze the pattern of hyperpigmentation on melasma. this was a descriptive-analytic study used a cross-sectional method that was performed in 2019 at two different dermatology and venerology clinics in indonesia, cipto mangunkusumo hospital jakarta and gatot subroto army hospital jakarta. forty-eight subjects with melasma, 50% diagnosed with mild melasma and 50% with moderate-severe melasma according to the modified melasma area and severity index (mmasi) score. the level of serum ft4 and tsh were then measured in both groups of the patients.

melasma has been suspected to be linked with thyroid hormone. there is no study that explains the association of thyroid hormone level with melasma severity. this study aims to find the difference in the levels of thyroid hormone in varying severity of melasma. this was a descriptive-analytic study used a cross-sectional method that was performed in 2019 at two different dermatology and venerology clinics in indonesia, cipto mangunkusumo hospital jakarta and gatot subroto army hospital jakarta. forty eight patients participated in this study, 50% diagnosed with mild melasma and 50% with moderate-severe melasma. subjects are chosen consecutively based on mmasi and janus ii measurement. the level of serum ft4 and tsh were then measured in both groups of the patients. the data is tabulated and a comparative analysis of serum ft4 and tsh levels with mild and moderate-severe melasma is done. in addition, this study also analyzes the level of serum ft4 and tsh with the result of janus ii facial analysis system scoring. the same method of analysis was done to know the association between mmasi and examination by using janus ii facial analysis system. this study aims to find the difference in the levels of thyroid hormone in varying severity of melasma.

Eligibility criteria:
inclusion criteria: * age 20-50 years * melasma lesions on the facial area. * willing to be the subject of research and sign a letter of research approval after being given an explanation (informed consent) exclusion criteria: * pregnancy * history of thyroid disease * using drugs that can affect the thyroid (glucocorticoids, lithium, amiodarone, iodide, octreotide) * using hormonal contraception for the past 1 year * using anti-seizure drugs * using hormone replacement therapy (hrt) * brown spots on the face preceded by reddish spots * brown spots on the face preceded by contact with facial whitening ingredients (hydroquinone)

Keywords: mmasi janus ii facial analysis system tsh ft4
telehealth after stroke care: integrated multidisciplinary access to post-stroke care

Conditions: Stroke; Health Care Acceptability; Hypertension

Summary: the telehealth after stroke care (tasc) trial is a pilot randomized controlled trial. it aims to evaluate the feasibility of a telehealth based model providing multidisciplinary access including nursing, pharmacy and physician care, and obtain preliminary evidence of efficacy of an integrated telehealth approach to blood pressure management after stroke.

hypertension is the most modifiable risk factor for recurrent stroke. blood pressure (bp) reduction is associated with decreased risk of stroke recurrence but remains poorly controlled in most survivors. minority groups have a higher prevalence of uncontrolled bp and higher rates of stroke. limited access contributes to challenges in post-stroke care. telehealth after stroke care (tasc) will be a telehealth intervention that integrates remote bp monitoring and telehealth visits to enhance bp control and promote self-efficacy, with a multidisciplinary approach to improve clinical processes and health outcomes. the investigators will assess for feasibility and obtain preliminary evidence of efficacy. fifty (50) eligible patients will be screened for inclusion prior to hospital discharge and randomized to tasc or usual care. tasc patients will receive a bp monitoring kit and electronic tablet. they will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy at 4 and 8 weeks and stroke neurologist. usual care patients will be seen by a primary care nurse practitioner at 1-2 weeks and a stroke neurologist at 1 and 3 months. data will be collected at 0 and 3 months. the primary outcome will be bp control (bp \<140/90 mmhg) at 3 months. the secondary outcome will be self-efficacy in medication adherence and treatment. interdisciplinary team competency, fidelity, and telehealth satisfaction surveys will be administered. patient reported outcomes including depression, cognitive function, and socioeconomic determinants will also be collected. integrated team-based interventions are needed to improve bp control and reduce racial disparities in post-stroke care. it may be feasible and effective in enhancing post-stroke bp control and promoting self-efficacy.

Eligibility criteria:
inclusion criteria: * presence of hypertension (by clinical history or hospital bp ≥140/90 on two occasions) * plan for discharge home after stroke * ability to provide consent (patient or caregiver) exclusion criteria: * modified rankin scale ≥ 4 at time of enrollment (severely disabled) * pregnancy * severe psychiatric illness * dialysis or diagnosis of end stage renal disease * life expectancy \< 1 year or terminal illness * symptomatic flow limiting cerebrovascular stenosis without plan for intervention, or long-term bp goal ≥ 140/90

Keywords: telehealth blood pressure (bp)
comparing exenatide and insulin glargine in type 2 diabetes patients for whom insulin is the next appropriate therapy

Conditions: Type 2 Diabetes Mellitus

Summary: this is a study with two treatment sequences and two treatment periods that will assess the safety and efficacy of exenatide treatment in patients with type 2 diabetes who have inadequate glycemic control using metformin or sulfonylurea and for whom insulin is the next appropriate step in diabetes treatment.


Eligibility criteria:
main inclusion criteria: * treated with a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. * hba1c between 7.1% and 11.0%, inclusive. * insulin therapy should be the next appropriate step of diabetes treatment. * body mass index (bmi) \>25 kg/m2 and \<40 kg/m2. main exclusion criteria: * patient previously in a study involving exenatide or glucagon-like peptide-1 analogs. * treated with insulin, thiazolidinediones, alpha-glucosidase inhibitors, or meglitinides within 3 months prior to screening.

Keywords: exenatide exendin-4 diabetes amylin lilly
"hyaluronan" formulation for dry mouth in sleep apnea patients

Conditions: Dry Mouth; Xerostomia; OSA; Sleep Apnea

Summary: during routine clinical practice, it is observed that patients with suspected obstructive sleep apnea (osa) often reported waking up with a dry mouth during the night or in the morning. this 9 week, cross-over group, randomized, single center, study will evaluate the efficacy of a proprietary formulation in comforting dry mouth in sleep apnea patients.


Eligibility criteria:
inclusion criteria: 1. patient should be above 18 years of age. 2. patients who have been initiated on cpap therapy after an initial diagnosis of osas and have developed dry mouth or have worsening of pre-existing dry mouth condition, as an effect of cpap therapy. 3. ability to attend visits at the research site 4. patient should be able to read and/or understand and sign the consent form and be willing to participate in the research study 5. have a negative history of radiation therapy to head and neck 6. agree to abstain from the use of any products for xerostomia other than those provided in the study. 7. agree to comply with the conditions and schedule of the study. exclusion criteria: 1. subjects with open mouth sores at study entry. 2. any pathology that, based on the judgement of the researcher, could negatively affect the oral mucosa and subsequent treatment for xerostomia (immune disorders, etc.) 3. subjects who are nursing, becoming pregnant or plan to become pregnant during the study period 4. subjects currently on medication or treatment for dry mouth/xerostomia 5. subjects \< 18 years of age 6. hypersensitivity to any of the following ingredients- ha ,xylitol and sodium benzoate. 7. subjects with soft or hard tissue tumor of the oral cavity. 8. presence of severe gingivitis 9. chronic disease with concomitant oral manifestations other than xerostomia 10. subjects with conditions the investigator may feel will interfere with the condition under study.
on the brink: photobiomodulation (pbm) for mucositis in patients undergoing allogeneic hematopoietic stem cell transplant (hsct) - implementing the evidence & discovering new knowledge

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Summary: this study evaluates mucositis and other oral symptoms in patients undergoing photobiomodulation in patients undergoing hematopoietic stem cell transplantation.

primary objective: i. examine mucositis severity, oral pain, taste changes, and xerostomia in patients undergoing pbm, a new standard of care for oral mucositis. outline: this is an observational study. participants are assigned to 1 of 2 groups. group i: patients have their medical records reviewed on study. group ii: nurses complete surveys on study.

Eligibility criteria:
inclusion criteria: * patients: * age: ≥ 18 years * undergoing allogeneic hsct - cases where pbm was used and cases where pbm was not used nurses: * nurses who administer pbm
efficacy of audio-visual-perception-enhancement (avwf®) method in chronic pain patients

Conditions: Pain; Stress

Summary: it is anticipated that audio-visual-perception-enhancement (avwf®) method leads to pain reduction and a decrease of inflammatory markers in chronic pain patients. also an improvement of quality of life, self-perceived disability and depression in chronic pain patients is expected.


Eligibility criteria:
inclusion criteria: * chronic low back pain with a numeric rating scale of pain \>= 4 for \> 6 month * patients \>18 years exclusion criteria: * psychosis * drug addiction * pension process * pregnant women * epilepsy

Keywords: pain stress avwf audio-visual-perception-enhancement
light therapy device for neonatal intraventricular hemorrhage grade 3 and 4

Conditions: Intraventricular Hemorrhage of Prematurity; Hydrocephalus

Summary: the primary purpose of this study is to serve as a pilot study of the efil device treatment feasibility of ivh grades 3,4 to guide development of a larger trial. primary outcomes will assess the following: safety of intervention, recruitment and consent process, acceptability of intervention by parents, retention rates, selection of most appropriate outcome measures, provide sample size estimates for a larger trial, increase the researchers\&#39; experience with the study intervention. a complete list of objectives and aims are listed under "objectives". this study hopes to treat 12-24 neonates using 650nm light of irradiance 10mw/cm2 for 5 minutes twice a day each day for 12 days. we will also call the parents at 6 months and 12 months to track developmental milestones.


Eligibility criteria:
inclusion criteria: * neonates with intraventricular hemorrhage grade 3 or 4 less than 1 month old. exclusion criteria: * neonates without ivh grade 3/4 or older than 1 month.

Keywords: low level laser therapy neonate developmental milestones intraventricular hemorrhage
home treatment of patients with pulmonary embolism based on pro-brain natriuretic peptide (bnp) levels

Conditions: Pulmonary Embolism

Summary: the aim of this study is to investigate the safety of treatment of pulmonary embolism in an outpatient setting based on normal pro-bnp levels. the mortality rate and the incidence of hemodynamic instability as well as major bleeding and recurrent venous thromboembolism (vte) in the outpatient group will be studied.

pulmonary embolism is a major health problem. because of risk for early hemodynamic instability and mortality, all patients with a recently diagnosed pulmonary embolism are treated in hospital. the clinical course of most patients is without complications. in practice most of the patients are only waiting in hospital in a good, clinical stable condition until their inr range is stable. this prospective management study is to investigate the safety of treatment of pulmonary embolism in an outpatient setting based on normal pro-bnp levels (\< 500 pg/ml). the incidence of complications due to the pulmonary embolism or its treatment will be followed during the first ten days of treatment.

Eligibility criteria:
inclusion criteria: * outpatient with a pulmonary embolism, confirmed by locally approved guidelines * aged 18 years and above * written informed consent exclusion criteria: * hemodynamic or respiratory instability defined as one of the following; hypotension rr systolic\ 100 bpm, need for oxygen therapy to maintain oxygen saturation above 90 %, collapse * illness unrelated to pe for which the patient would require hospitalization * pain requiring intravenous narcotics * thrombolysis * active bleeding or thrombopathy * pregnancy * in hospital patients * physical or psychiatric inability for home treatment * no support system at home renal insufficiency

Keywords: pulmonary embolism pro-bnp home treatment
insulin therapy in the hospital comparing two protocols

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine if by using insulin analog (glargine and lispro insulin) with an insulin pen the investigators are able to obtain a higher rate of correct timing of insulin and food administration as when compared to the usual therapy (insulin nph and regular) with syringes.


Eligibility criteria:
inclusion criteria: * uncontrolled blood sugar: * random blood sugar ≥ 200mg/dl * pre-prandial blood sugar greater than 180 mg/dl on two occasions within 24 hours. * patient may be off insulin or on subcutaneous inpatient insulin regimen less than 36 hours. * transition from an insulin drip in the intensive care units to subcutaneous insulin upon transfer to general ward. * patient is able to eat and oral feeding is expected. exclusion criteria: * patients receiving inpatient oral hypoglycemic agents * patients with chronic kidney disease stages 4 \& 5 (estimated gfr of \<30ml/min) and on dialysis * patient with chronic liver disease * patient with hypoglycemia unawareness * pregnancy * patients who are on "npo" for medical reasons. * patient is expected to stay in the hospital for less than 3 days. * patient on a new inpatient insulin regimen for \> 36 hours.

Keywords: diabetes inpatient insulin insulin pen
safety, efficacy assessment of geltim lp® 1 mg/g in ocular hypertensive or glaucomatous patients.

Conditions: Glaucoma

Summary: this phase iv study aims to assess the safety and the efficacy in intra ocular pressure of geltim lp® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of xalatan® with ocular objective signs of intolerance to prostaglandin eye drops.

the primary objectives are to compare the safety and the efficacy of geltim lp® 1mg/g eye drops versus xalatan® eye drops with respect to: the assessment of the ocular tolerance: * ocular symptoms * objective ocular signs. the maintain of the iop efficient lowering effect. comparison between the 2 study products of the mean basal iop after a 12 weeks treatment period (84 days ±7).

Eligibility criteria:
inclusion criteria: * written informed consent. * association of the 4 following criteria: 1. - bilateral primary open angle glaucoma or bilateral ocular hypertension already treated and controlled by mono-therapy of xalatan® (1drop per day), 2. - with local intolerance signs. exclusion criteria: * presence of severe objective ocular sign. * any ocular hypertension other than primary ocular hypertension or primary chronic open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma). * absolute defect in the ten degrees central point of the visual field. * best far corrected visual acuity ≤ 1/10.

Keywords: bilateral glaucoma bilateral ocular hypertension bilateral primary open angle glaucoma bilateral ocular hypertension already treated and controlled by mono-therapy of xalatan® (1drop per day) with local intolerance signs in at least one eye
obstructive sleep apnoea in adolescents with thoracic aortic aneurysm

Conditions: Thoracic Aortic Aneurysm Without Rupture; Obstructive Sleep Apnea

Summary: the objective of this prospective cohort study is to determine the prevalence of obstructive sleep apnoea (osa) in patients with and without thoracic aortic aneurysm.

the objective of this prospective cohort study is to determine the prevalence of obstructive sleep apnoea (osa) in patients with and without thoracic aortic aneurysm.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * diagnosis of thoracic aortic aneurysm defined by the following parameters: women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. (for controls: \<39mm and \<42mm respectively); men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm. (for controls: \<44mm and \<46mm respectively) exclusion criteria: * patients on continuous positive airway pressure (cpap) therapy for osa at baseline. * patients with known central sleep apnoea. * patients on morphine or other opioid medication, heroin addiction, alcohol addiction. * patients with moderate or severe aortic regurgitation. * patients with moderate or severe aortic stenosis. * pregnant patients.

Keywords: thoracic aortic aneurysm obstructive sleep apnea